Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors

Clinical trial NCT01239134 · COMPLETED

Trial details

NCT number: NCT01239134
Sponsor: Leap Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies

Start date: 2010-10-01
Primary completion: 2018-09-01
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.